Biologics
Orthofix and IsoTis Biologics are engineered to facilitate bony fusion for spine, orthopedics, and other surgical applications. Our comprehensive portfolio of differentiated bone graft solutions includes rigorously studied cellular bone allografts, premium fiber and putty demineralized bone matrices (DBMs), advanced bioactive synthetics, and procedural solutions for streamlined surgical applications.
Developed by dedicated research and development teams at our in-house tissue bank in Irvine, CA, or in collaboration with MTF Biologics® in Edison, NJ, our products reflect a commitment to innovation, quality, and patient care. With validation from multiple peer-reviewed studies research studies, Orthofix and IsoTis Biologics demonstrate robust bone growth and successful clinical outcomes through their osteoconductive, osteoinductive, and/or osteogenic properties.
Orthofix Biologics
Orthofix Biologics brings together a comprehensive portfolio of bone graft solutions developed through dedicated R&D at our in-house tissue bank in Irvine, California, and through our collaboration with MTF Biologics in Edison, New Jersey. Following the 2023 merger with SeaSpine, the combined portfolio expanded Orthofix’s biologics offering across cellular allografts, DBMs, synthetics, and procedural solutions.
IsoTis Biologics
IsoTis Biologics represents Orthofix’s established in-house orthobiologics platform, with products developed by dedicated R&D teams at our tissue bank in Irvine, California. The portfolio includes DBM fibers and putties, advanced synthetics, procedural solutions, and traditional allografts designed to support a broad range of bone grafting applications.
Follow Us on LinkedIn
Stay up to date on the latest news, education, and insights from Orthofix Biologics
